Company
TSE:NUMI
Numinus Wellness helps people to heal and be well through the development and delivery of innovative mental health care and access to safe, evidence-based psychedelic-assisted therapies. The Numinus model – including psychedelic production, research and clinic care – is at the forefront of a transformation aimed at healing rather than managing symptoms for depression, anxiety, trauma, pain and substance use. At Numinus, we are leading the integration of psychedelic-assisted therapies into mainstream clinical practice and building the foundation for a healthier society.
74 stories · page 4 of 4
Numinus plans to use the candidate mushroom clone to develop a uniform all-natural psilocybin capsule for use in Optimi's human clinical trials
The trial, which involved 90 participants with chronic PTSD, demonstrated that 88% of participants who received three controlled and supervised MDMA-assisted therapy sessions experienced a clinically significant reduction in symptoms, with
Subsequent to the quarter-end, Numinus completed a $40.25 million financing and raised an additional $1.5 million from warrant exercises, putting its current cash balance at around $65 million
Archive
A glance at some of the day's highlights from the Proactive Investors US and Canada newswires
The trial will enroll 14 human volunteers and assess the safety and psychoactive properties of a psilocybe mushroom product extracted and formulated at the Numinus Bioscience lab in British Columbia
The over-allotment option saw an additional 4,200,000 units purchased for additional gross proceeds of $5.25 million
The company said the underwriters, Eight Capital and Canaccord Genuity have now agreed to purchase an aggregate of 28,000,000 Numinus units at a price of $1.25 each, up from 24.000 initially
The firm is the only Canadian public company licensed to work with the full range of psychedelics and to produce and extract psilocybin from mushrooms
It said the 7,500 square foot expansion will "enhance our IP and partnerships strategy, generate more revenue through analytics testing for psychedelics and other contract services, and increase our supply of consistent, safe and effective
The company's Bioscience unit recently received amendments to its federal licence to allow the possession, production, assembly, sale, export, and delivery for a wide variety of psychedelics including – for the first time – ketamine and LSD
The company said that it has finalized the PRIME study protocol and appointed co-principal investigators to the study
The study, which is in collaboration with MAPS Public Benefit Corporation (MAPS PBC), subsidiary of the Multidisciplinary Association for Psychedelic Studies (MAPS), has successfully transitioned into the 'pre-implementation stage' at Numin
The acquisition expands Numinus' presence into Quebec, building on its Vancouver office with two established locations and extensive virtual services as well as insights garnered from a decade of successful clinic management.
During the three-month period to end November 20, 2020, Numinus generated revenue of C$229,188 and ended the quarter with a cash balance of C$4,915,209
